



Automated mining a database of 9.4M reactions from the patent literature, and its application to synthesis planning


Roger Sayle, John Mayfield and Ingvar Lagerstedt

NextMove Software, Cambridge, UK

Daniel Lowe, Minesoft, Cambridge, UK



PISTACHIO: A DATABASE OF 9.3M RXNS



3-chloro-6-(trifluoromethyl)pyridazine product

🔍


🔗 (1..21) of 21 details 47 ms
 Group Abbreviate Align

Named Reactions

- ➔ Functional group interconversion (FGI) 21
 - ➔ Other functional group interconversion 16
 - Iodo to trifluoromethyl 10
 - Pyridone to chloropyridine 6
 - ➔ Alcohol to halide 5
 - Hydroxy to chloro 5


Date

1988: 0



Yield

16: 0








Assignee

- Syngenta 9
- Ea Pharma Co. 8
- Nihon Nohyaku Co. 2
- Takeda 1
- Pillsbury Winthrop Shaw Pittman 1
- Kalypsys 1

Diseases

- ➔ Nervous System Diseases 10
 - ➕ Neuromuscular Diseases 9
 - ➕ Neurologic Manifestations 8
 - ➕ Central Nervous System Diseases 2
 - ➕ Neurodegenerative Diseases 1
- ➕ Endocrine System Diseases 10

Displaying 3-chloro-6-(trifluoromethyl)pyridazine product
EXACT

	<input type="checkbox"/> US20050234046A1 [0528]	20-Oct-2005	Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders	Iodo to trifluoromethyl
	<input type="checkbox"/> US20060148858A1 [1084]	06-Jul-2006	1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity	92 Pyridone to chloropyridine
	<input type="checkbox"/> US20160021886A1 [C00007]	28-Jan-2016	Condensed Heterocyclic Compound Or Salt Thereof, Agricultural And Horticultural Insecticide Comprising The Compound, And Method For Using The Insecticide	Hydroxy to chloro
	<input type="checkbox"/> US20160332999A1 [0548]	17-Nov-2016	Heterocyclic Sulfonamide Derivative And Medicine Comprising Same	63 Pyridone to chloropyridine
	<input type="checkbox"/> US20160332999A1 [0763]	17-Nov-2016	Heterocyclic Sulfonamide Derivative And Medicine Comprising Same	85 Hydroxy to chloro

TEXT MINING: US20160332999A1



US 20160332999A1

(19) **United States**

(12) **Patent Application Publication**
KOBAYASHI et al.

(10) **Pub. No.: US 2016/0332999 A1**
(43) **Pub. Date: Nov. 17, 2016**

(54) **HETEROCYCLIC SULFONAMIDE
DERIVATIVE AND MEDICINE COMPRISING
SAME**

(71) Applicant: **EA PHARMA CO., LTD.**, Tokyo (JP)

(72) Inventors: **Kaori KOBAYASHI**, Kawasaki-shi (JP); **Tamotsu SUZUKI**, Kawasaki-shi (JP); **Mizuki KAWAHIRA**, Kawasaki-shi (JP); **Tomohiro FUJII**, Kawasaki-shi (JP); **Masayuki SUGIKI**, Kawasaki-shi (JP); **Koji OHSUMI**, Kawasaki-shi (JP); **Tatsuya OKUZUMI**, Tokyo (JP)

(73) Assignee: **EA PHARMA CO., LTD.**, Tokyo (JP)

(21) Appl. No.: **15/222,178**

(22) Filed: **Jul. 28, 2016**

Related U.S. Application Data

(63) Continuation of application No. PCT/JP2015/052415, filed on Jan. 28, 2015.

Foreign Application Priority Data

Jan. 28, 2014 (JP) 2014-013729
Aug. 6, 2014 (JP) 2014-160250

Publication Classification


(51) **Int. Cl.**
C07D 405/14 (2006.01)
C07D 405/12 (2006.01)

C07D 413/14 (2006.01)
C07D 407/12 (2006.01)
C07D 491/048 (2006.01)
C07D 498/04 (2006.01)
C07D 307/82 (2006.01)
C07D 409/14 (2006.01)

(52) **U.S. Cl.**
CPC **C07D 405/14** (2013.01); **C07D 307/82** (2013.01); **C07D 405/12** (2013.01); **C07D 409/14** (2013.01); **C07D 407/12** (2013.01); **C07D 491/048** (2013.01); **C07D 498/04** (2013.01); **C07D 413/14** (2013.01)

(57) **ABSTRACT**

The present invention provides a compound represented by the formula (I):



wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.




TEXT MINING: US20160332999A1

Reference Example D-35

Synthesis of [4-[6-(trifluoromethyl)pyridazin-3-yl]-2-pyridyl]methylamine hydrochloride (D-35)

[0547]



(step 1) Synthesis of
3-chloro-6-(trifluoromethyl)pyridazine

[0548] To 3-(trifluoromethyl)-1H-pyridazin-6-one (1.1 g, 6.7 mmol) was added phosphorus oxychloride (10 mL) and the mixture was stirred at 100° C. for 2.5 hr, and concentrated under reduced pressure. To the obtained residue were added dichloromethane and water, and the mixture was stirred at room temperature for 5 min. The mixture was alkalinized by adding potassium carbonate to partition the mixture. The organic layer was washed with saturated brine, dried over sodium sulfate, and the desiccant was filtered off, and the solvent was evaporated and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to give the title compound (0.77 g, 4.2 mmol, 63%).

[0549] MS (ESI) m/z 182 (M+H)⁺

[0550] ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J=8.8 Hz, 1H), 7.74 (d, J=8.8 Hz, 1H).

(step 2) Synthesis of [4-[6-(trifluoromethyl)pyridazin-3-yl]-2-pyridyl]methylamine hydrochloride (D-35)

[0551] Using the compound obtained in step 1 instead of 5-bromo-2-(trifluoromethyl)pyrimidine, and by an operation similar to that in Reference Example D-32, step 2, the title compound was obtained (yield 54%).


[0552] MS (ESI) m/z 255 (M+H)⁺

[0553] ¹H NMR (400 MHz, CD₃OD) δ 8.92 (d, J=5.3 Hz, 1H), 8.59 (d, J=9.0 Hz, 1H), 8.37 (br s, 1H), 8.33 (d, J=9.0 Hz, 1H), 8.24 (dd, J=5.3, 1.4 Hz, 1H), 4.49 (s, 2H).

Reference Example D-36

Synthesis of [5-[6-(trifluoromethyl)-3-pyridyl]-3-pyridyl]methylamine (D-36)

[0554]



[0555] Using 5-bromo-2-trifluoromethylpyridine and (5-cyano-3-pyridyl)boronic acid instead of 5-bromo-2-trif-



TEXT MINING: US20160332999A1

US20160332999A1

e.g. US6356863 or US2007129372

[+] Show advanced options

Navigation **Chemical Data**

Abstract Description Claims


Table navigation:

<input checked="" type="checkbox"/>	Entity type	Count (unique)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Physquant	3919 (1206)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Mol	3210 (1276)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Reference	946 (354)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Generic	645 (105)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Prefix	546 (237)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	NMR	542 (542)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	MechanismOfAction	522 (34)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Formula	449 (28)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	DictMol	369 (27)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	SolventMixture	222 (28)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	MassSpec	221 (141)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	DiseaseGrammar	195 (55)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Exp. Procedure	195 (7)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	GeneOrProtein	132 (15)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	SolventMixtureNew	127 (8)	<input type="button" value="←"/>	<input type="button" value="→"/>
<input checked="" type="checkbox"/>	Markush	122 (33)	<input type="button" value="←"/>	<input type="button" value="→"/>

Reference Example D-35

Synthesis of [4-[6-(trifluoromethyl)pyridazin-3-yl]-2-pyridyl]methylamine hydrochloride (D-35)

[0547]



(step 1) Synthesis of 3-chloro-6-(trifluoromethyl)pyridazine

[0548]

To 3-(trifluoromethyl)-1H-pyridazin-6-one (1.1 g, 6.7 mmol) was added phosphorus oxychloride (10 mL) and the mixture was stirred at 100° C. for 2.5 hr, and concentrated under reduced pressure. To the obtained residue were added dichloromethane and water, and the mixture was stirred at room temperature for 5 min. The mixture was alkalinified by adding potassium carbonate to partition the mixture. The organic layer was washed with saturated brine, dried over sodium sulfate, and the desiccant was filtered off, and the solvent was evaporated and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to give the title compound (0.77 g, 4.2 mmol, 63%).

[0549]

MS (ESI) m/z 182 (M+H)⁺

[0550]


¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, J=8.8 Hz, 1H), 7.74 (d, J=8.8 Hz, 1H).



TEXT MINING: US20160332999A1

Pistachio
Atom Mapping: Color None Number Abbreviate: Align:

NMSR:3216924



Pyridone to chloropyridine (9.7.112)

Name	Role	Formula	MW	Amount	Mass	Volume	Density	Yield
3-chloro-6-(trifluoromethyl)pyridazine	Product	C ₅ H ₂ ClF ₃ N ₂	182.531 g/mol	4.2 mmol	770 mg			63 %
3-(trifluoromethyl)-1H-pyridazin-6-one	Reactant	C ₅ H ₃ F ₃ N ₂ O	164.086 g/mol	6.7 mmol	1.1 g			
phosphorus oxychloride	Solvent	Cl ₃ OP	153.332 g/mol			10 mL		

Info

Source	US20160332999A1 [0548]
Document	Kaori Kobayashi, Tamotsu Suzuki, Mizuki Kawahira, Tomohiro Fujii, Masayuki Sugiki, Koji Ohsumi, Tatsuya Okuzumi Heterocyclic Sulfonamide Derivative And Medicine Comprising Same U.S. Application (17-Nov-2016)
Affiliation	Ea Pharma Co.
IPC Codes	C07D 307/82, C07D 405/12, C07D 405/14, C07D 407/12, C07D 409/14, C07D 413/14, C07D 491/048, C07D 498/04
Diseases	Acute Pain, Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Pain, Cough, Diabetic Neuropathies, Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Osteoarthritis, Pancreatitis, Peptic Esophagitis, Pruritus
Targets	Transient receptor potential cation channel subfamily A member 1

Procedure

(step 1) Synthesis of 3-chloro-6-(trifluoromethyl)pyridazine

To 3-(trifluoromethyl)-1H-pyridazin-6-one (1.1 g, 6.7 mmol) was added phosphorus oxychloride (10 mL) and the mixture was stirred at 100° C. for 2.5 hr, and concentrated under reduced pressure. To the obtained residue were added dichloromethane and water, and the mixture was stirred at room temperature for 5 min. The mixture was alkalinized by adding potassium carbonate to partition the mixture. The organic layer was washed with saturated brine, dried over sodium sulfate, and the desiccant was filtered off, and the solvent was evaporated and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to give the title compound (0.77 g, 4.2 mmol, 63%).

Identifiers

SMILES	O=[c:1]1[cH:2][cH:3][c:4]([n:5][nH:6]1)[C:7]([F:8])([F:9])[F:10].O=P(Cl)(Cl)[Cl:11]>>[F:8][C:7]([F:9])([F:10])[c:4]1[cH:3][cH:2][c:1]([n:6][n:5]1)[Cl:11]
RInChI	RInChI=1.00.1S/C5H2ClF3N2/c6-4-2-1-3(10-11-4)5(7,8)9/h1-2H<>C5H3F3N2O/c6-5(7,8)3-1-2-4(11)10-9-3/h1-2H,(H,10,11)<>Cl3OP/c1-5(2,3)4/d-



TEXT MINING: US20160332999A1

```
{"data":{"paragraphText":"To 3-(trifluoromethyl)-1H-pyridazin-6-one (1.1 g, 6.7 mmol) was added phosphorus oxychloride (10 mL) and the mixture was stirred at 100° C. for 2.5 hr, and concentrated under reduced pressure. To the obtained residue were added dichloromethane and water, and the mixture was stirred at room temperature for 5 min. The mixture was alkalified by adding potassium carbonate to partition the mixture. The organic layer was washed with saturated brine, dried over sodium sulfate, and the desiccant was filtered off, and the solvent was evaporated and the obtained residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate) to give the title compound (0.77 g, 4.2 mmol, 63%).","headingText":"(step 1) Synthesis of 3-chloro-6-(trifluoromethyl)pyridazine", "documentId":"US20160332999A1", "title":"Heterocyclic Sulfonamide Derivative And Medicine Comprising Same", "assignees":["Ea Pharma Co."], "authors":["Kaori Kobayashi", "Tamotsu Suzuki", "Mizuki Kawahira", "Tomohiro Fujii", "Masayuki Sugiki", "Koji Ohsumi", "Tatsuya Okuzumi"], "source":"USPTO_TEXT_A", "reactionSmiles":"O=[c:1]1[cH:2][cH:3][c:4]([n:5][nH:6]1)[C:7]([F:8])([F:9])[F:10].O=P(Cl)(Cl)[Cl:11]>>[F:8][C:7]([F:9])([F:10])[c:4]1[cH:3][cH:2][c:1]([n:6][n:5]1)[Cl:11]", "smiles":"O=[c:1]1[cH:2][cH:3][c:4]([n:5][nH:6]1)[C:7]([F:8])([F:9])[F:10].O=P(Cl)(Cl)[Cl:11]>>[F:8][C:7]([F:9])([F:10])[c:4]1[cH:3][cH:2][c:1]([n:6][n:5]1)[Cl:11]", "ipcCodes":["C07D 307/82", "C07D 405/12", "C07D 405/14", "C07D 407/12", "C07D 409/14", "C07D 413/14", "C07D 491/048", "C07D 498/04"], "date":"17-Nov-2016", "namerxndef":"Pyridone to chloropyridine (9.7.112)", "namerxn":"9.7.112", "diseases":["Acute Pain", "Asthma", "Atopic Dermatitis", "Chronic Obstructive Pulmonary Disease", "Chronic Pain", "Cough", "Diabetic Neuropathies", "Inflammatory Bowel Diseases", "Irritable Bowel Syndrome", "Osteoarthritis", "Pancreatitis", "Peptic Esophagitis", "Pruritus"], "targets":["Transient receptor potential cation channel subfamily A member 1"], "location":"548", "rinchi":"RInChI=1.00.1S/C5H2ClF3N2/c6-4-2-1-3(10-11-4)5(7,8)9/h1-2H<>C5H3F3N2O/c6-5(7,8)3-1-2-4(11)10-9-3/h1-2H,(H,10,11)<>Cl3OP/c1-5(2,3)4/d-"}, "components":[{"role":"Product", "name":"3-chloro-6-(trifluoromethyl)pyridazine", "smiles":"ClC=1N=NC(=CC1)C(F)(F)F", "quantities":[{"type":"Amount", "value":0.0042, "text":"4.2 mmol"}, {"type":"Mass", "value":0.77, "text":"0.77 g"}, {"type":"Yield", "value":63.0, "text":"63%"}], "molWeight":182.5311146438476, "molFormula":"C<sub>5</sub>H<sub>2</sub>ClF<sub>3</sub>N<sub>2</sub>"}, {"role":"Reactant", "name":"3-(trifluoromethyl)-1H-pyridazin-6-one", "smiles":"FC(Cl=NNC(C=Cl)=O)(F)F", "quantities":[{"type":"Amount", "value":0.0067, "text":"6.7 mmol"}, {"type":"Mass", "value":1.1, "text":"1.1 g"}], "molWeight":164.08552274705877, "molFormula":"C<sub>5</sub>H<sub>3</sub>F<sub>3</sub>N<sub>2</sub>O"}, {"role":"Solvent", "name":"phosphorus oxychloride", "smiles":"O=P(Cl)(Cl)Cl", "quantities":[{"type":"Volume", "value":0.01, "text":"10 mL"}], "molWeight":153.3319792921214, "molFormula":"Cl<sub>3</sub>OP"}]}
```



INTRODUCTION SUMMARY

- NextMove Software use text mining to automatically extract a database of chemical reactions from the patent literature.



PISTACHIO: ALEXA/SIRI FOR CHEMISTS

30-40% yield Merck LiOH deprotections in the last six months indazole substructure



Displaying

30-40% yield
YIELD

Merck
ASSIGNEE


LiOH
EXACT

deprotections
REACTION_TYPE

in the

last six months
BEG_DATE

indazole substructure
SUBSTRUCTURE



[US09663522B2 \[0316\]](#) 30-May-2017 3-Aminocycloalkyl Compounds As Rorgammat Inhibitors And Uses Thereof (35) CO2H-Me deprotection



Automated Extraction of Reactions from the Patent Literature



Daniel Lowe

Unilever Centre for Molecular Science Informatics
University of Cambridge



NEXTMOVE'S FREE "USPTO" DATA SET

→ nextmovesoftware.com/blog/2014/02/27/unleashing-over-a-million-reactions-into-the-wild/


Unleashing over a million reactions into the wild

Posted on [February 27, 2014](#) by [daniel](#)

Unlike with small molecules, there are currently no large sets of publically available reaction data.

To remedy this situation, we have extracted over a million reactions from United States patent applications (2001-2013) and the same again from patent grants (1976-2013). This contrasts to the original data release of "only" 420 thousand (from 2008-2011 applications) whilst I was in the [PMR](#) group.

The reactions are available as reaction SMILES or CML from [here](#), as [7zip](#) archives. The CML representation includes quantities and yields where these were found. A documentation zip provides further information on the format of the data. This data is made available under [CC-Zero](#) i.e. without copyright.




REACTION DATABASE LANDSCAPE

- Manually curated databases
 - Elsevier Reaxys
 - CAS SciFinder
 - InfoChem SPRESI
- Machine curated databases
 - USPTO
 - Pistachio
- Evaluation Metrics
 - Availability/Price
 - Coverage/Size/Frequency
 - Quality/Annotation



PISTACHIO WORKFLOW




CURRENT PISTACHIO STATISTICS

• U.S. Application Text	2,902,949	2020-02-27
• U.S. Grant Text	2,662,420	2020-02-25
• EPO Application Text	553,143	2020-02-19
• EPO Grant Text	866,530	2020-02-19
• U.S. Application Sketches	1,419,737	2020-02-27
• U.S. Grant Sketches	915,226	2020-02-25
• Total	9,320,005	
• Unique (parents)	2,945,919	



TOTAL REACTIONS OVER TIME




5.3TB SOURCE "BIG DATA"

- /patents/applications
 - 6,085,900 2001-2020 2.2TB
- /patents/grants
 - 7,305,481 1976-2020 1.5TB
- /patents/ep
 - 1,871,242 2013-2020 1.1TB [1978-]
- /patents/epo
 - 3,516,326 1978-2013 492GB €20K



EXAMPLE ENTITY DICTIONARY AS DAG



- Nitrogen containing heterocycles as minimal DFA:
 - Pyrrole, Pyrazole, Imidazole, Pyrdine, Pyridazine, Pyrimidine, Pyrazine
- CaffeineFix supports (very large) user dictionaries.



SPELLING CORRECTION

di-ter~~f~~-butyl (4S)-/~~V~~-(~~f~~ert-butoxycarbonyl)-4-{4-[3-(tosyloxy)propyl]benzyl}-L-glutamate

CaffeineFix corrected to:


di-ter~~t~~-butyl (4S)-~~N~~-(~~t~~ert-butoxycarbonyl)-4-{4-[3-(tosyloxy)propyl]benzyl}-L-glutamate



RULE-BASE TEXT-MINING SPEED

BioCreAtIvE V challenge
evaluating text-mining and
extraction systems.

Web service **response time** to
annotate an **abstract** evaluated for
CDR task.



Chih-Hsuan Wei et al. Assessing the state of the art in biomedical relation extraction: overview of the BioCreative V chemical-disease relation (CDR) task. [Database \(Oxford\)](#). 2016; 2016: baw032. [PMC4799720](#)




RULE-BASE TEXT-MINING SPEED

BioCreAtIvE V challenge
evaluating text-mining and
extraction systems.

Web service **response time** to
annotate an **abstract** evaluated for
CDR task.

Efficient rule-based text-mining
provides provenance for
annotations and can mine entire
back-archive of US patents in **~24
hours** on a single machine.



Chih-Hsuan Wei et al. Assessing the state of the art in biomedical relation extraction: overview of the BioCreative V chemical-disease relation (CDR) task. [Database \(Oxford\)](#). 2016; 2016: baw032. [PMC4799720](#)



ADVANCED ENTITY RECOGNITION

- Name2Structure improvements.
- Dictionaries and ontologies.
- Molecular formulae and line formulae
 - K_2CO_3 , $PdCl_2(PPh_3)_2$, $Pd(P(o-tolyl)_3)_2$, $PdCl_2(dppf)-CH_2Cl_2$
- Inorganics, organometallics and salts.
 - vanadium oxychloride, cupric chloride.
- Mixtures/Formulations.
 - 5% 2M methanolic ammonia/DCM, 10% H₂O₂ in water
- Apparatus.
 - A 1 L three necked round bottomed flask




CHEMDRAW SKETCH PROCESSING


Re-interpretation of ChemDraw sketches

1. Correct systematic errors
2. Extract extra semantics (structure variation, reaction schemes)
3. Categorise output (is this something we can't interpret)


US 2004/101442 C00025
Original Sketch



Default Interpretation
(USPTO molfile)



Our Interpretation




John May, *et al.* Sketchy Sketches: Hiding Chemistry in Plain Sight. Seventh Joint Sheffield Conference on Cheminformatics. 2016




REACTION SCHEME SKETCHES


Example 26, US 09718816 B2




Step 1




Step 2



Step 3



Step 4



etc..

John May, *et al.* Sketchy Sketches: Hiding Chemistry in Plain Sight. Seventh Joint Sheffield Conference on Cheminformatics. 2016



RESOLVING IDENTIFIERS

- Need to “name space” identifiers
 - “Compound 1”, “Reference compound 1”, “Example 1”
 - But “Compound 1” = “cmpd 1” = “cpd. #1”
- Identifier may be defined multiple times e.g. as a sketch and chemical name



RESOLVING IDENTIFIERS (TEXT-MINING)

EXAMPLE 3

1,2-Dihydro-2-(4-trifluoromethylphenyl)-5-(3-trifluoromethyl-2-pyridinyl)-3H-indazol-3-one


This compound was prepared as described for Example 1 replacing 2-azido-4-bromobenzoic acid with 2-azido-5-bromobenzoic acid in Step 2. ¹H NMR (360 MHz, DMSO): 7.52 (1H, d, J 8.0 Hz), 7.65-7.75 (1H, m), 7.76 (1H, dd, J 1.2 and 8.0 Hz), 7.83 (1H, s), 7.91 (2H, d, J 8.0 Hz), 8.18 (2H, d, J 8.0 Hz), 8.34 (1H, d, J 8.0 Hz), 8.9 (1H, d, J 8.0 Hz), 11.1 (1H, s).

EXAMPLE 4

1,2-Dihydro-6-(2-methoxyphenyl)-2-(4-trifluoromethylphenyl)-3H-indazol-3-one





RESOLVING IDENTIFIERS (SKETCHES)



RESOLVING IDENTIFIERS (TABLES)

TABLE 1

No.	Chemical Structure
I-1	
I-2	



R GROUP TABLES




TABLE 2

Ex. No.	Z ¹	Z ²	Z ³	R ¹	R ^{6a}	R ^{6b}	A ₄	A ₃	A ₂	A ₁	M ₁	M ₂	W	Q	logP ^{a)}	Mass ^{a)}
Ic-1	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-H	C-H	C-H	H	H	O	ethyl	3.59	496.2
Ic-2	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	ethyl	3.72	514.1
Ic-3	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	1,3-thiazol-yl	3.93	569.0
Ic-4	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	CH ₃	3.40	500.1
Ic-5	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	2,2,2-trifluoroethyl	3.93	568.0
Ic-6	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	trifluoromethyl	4.24	554.0
Ic-7	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	thiophen-2-ylmethyl	4.12	582.0
Ic-8	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-H	N	C-H	H	H	O	CH ₃	2.35	483.0

US 2016/0002208 A1



R GROUP TABLES





TABLE 2

Ex. No.	Z ¹	Z ²	Z ³	R ¹	R ^{6a}	R ^{6b}	A ₄	A ₃	A ₂	A ₁	M ₁	M ₂	W	Q	logP ^{a)}	Mass ^{a)}
Ic-1	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-H	C-H	C-H	H	H	O	ethyl	3.59	496.2
Ic-2	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	ethyl	3.72	514.1
Ic-3	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	1,3-thiazol-yl	3.93	569.0
Ic-4	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	CH ₃	3.40	500.1
Ic-5	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	2,2,2-trifluoroethyl	3.93	568.0
Ic-6	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	trifluoromethyl	4.24	554.0
Ic-7	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-F	C-H	C-H	H	H	O	thiophen-2-ylmethyl	4.12	582.0
Ic-8	C ₂ F ₅	CF ₃	CH ₃	H	H	H	C-H	C-H	N	C-H	H	H	O	CH ₃	2.35	483.0

US 2016/0002208 A1




ADDITIONAL ANNOTATION

- Company Ontology
 - Ciba-Giegy Corp. = Ciba-Giegy → Novartis
- Calculated Yields
 - Density of POCl_3 is 1.64 g/cm^3 .
- Reaction Steps/Recipes (ISA-88)
 - Add, Synthesize, Wait, Degass, Yield, Wash, Reflux, Irradiate, Stir, Extract, Precipitate, Mill, Remove, Filter, Partition, Sample, Heat, Concentrate, Dry, Quench, Cool, Transfer, Purify, Dissolve...



CATEGORIZATION OF REACTIONS



1. J. Carey, D. Laffan, C. Thomson, M. Williams, *Org. Biomol. Chem.* 2337, 2006.
2. S. Roughley and A. Jordan, *J. Med. Chem.* 54:3451-3479, 2011.



REACTION ONTOLOGY

- Reactions are classified into a common subset of the Carey et al. classes and the RSC's RXNO ontology.
- There are 12 super-classes
 - e.g. 3 C-C bond formation (RXNO:0000002).
- These contain 84 class/categories.
 - e.g. 3.5 Pd-catalyzed C-C bond formation (RXNO:0000316)
- These contain ~1150 named reactions/types.
 - e.g. 3.5.3 Negishi coupling (RXNO:0000088)
- These require ~2490 SMIRKS-like transformations.



Development of a Novel Fingerprint for Chemical Reactions and Its Application to Large-Scale Reaction Classification and Similarity


Nadine Schneider,[†] Daniel M. Lowe,[‡] Roger A. Sayle,[†] and Gregory A. Landrum^{*,†}

[†]Novartis Institutes for BioMedical Research, Novartis Campus, 4002 Basel, Switzerland

[‡]NextMove Software, Ltd., Innovation Centre, Unit 23, Science Park, Milton Road, Cambridge CB4 0EY, United Kingdom

Supporting Information

ABSTRACT: Fingerprint methods applied to molecules have proven to be useful for similarity determination and as inputs to machine-learning models. Here, we present the development of a new fingerprint for chemical reactions and validate its usefulness in building machine-learning models and in similarity assessment. Our final fingerprint is constructed as the difference of the atom-pair fingerprints of products and reactants and includes agents via calculated physicochemical properties. We validated the fingerprints on a large data set of reactions text-mined from granted United States patents from the last 40 years that have been classified using a substructure-based expert system. We applied machine learning to build a 50-class predictive model for reaction-type classification that correctly predicts 97% of the reactions in an external test set. Impressive accuracies were also observed when applying the classifier to reactions from an in-house electronic laboratory notebook. The performance of the novel fingerprint for assessing reaction similarity was evaluated by a cluster analysis that recovered 48 out of 50 of the reaction classes with a median F-score of 0.63 for the clusters. The data sets used for training and primary validation as well as all python scripts required to reproduce the analysis are provided in the Supporting Information.



Big Data from Pharmaceutical Patents: A Computational Analysis of Medicinal Chemists' Bread and Butter

Nadine Schneider[†], Daniel M. Lowe[‡], Roger A. Sayle[‡], Michael A. Tarselli[‡], and Gregory A. Landrum[†]

[†]Novartis Institutes for BioMedical Research, Novartis Pharma AG, Novartis Campus, 4002 Basel, Switzerland

[‡]Novartis Institutes for BioMedical Research, 186 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

[§]NextMove Software Ltd., Innovation Centre, Unit 23, Science Park, Milton Road, Cambridge CB4 0EY, U.K.

J. Med. Chem., 2016, 59 (9), pp 4385–4402

DOI: 10.1021/acs.jmedchem.6b00153


Publication Date (Web): March 30, 2016

Copyright © 2016 American Chemical Society

*E-mail: nadine-1.schneider@novartis.com

This article is part of the Computational Methods for Medicinal Chemistry special issue.

Abstract



Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store

BiomolecularGraphics4All Talk [Sandbox](#) [Preferences](#) [Beta](#) [Watchlist](#) [Contributions](#) [Log out](#)

Article [Talk](#) [Read](#) [Edit](#) [View history](#) [More](#)

Negishi coupling

From Wikipedia, the free encyclopedia

The **Negishi coupling** is a widely employed [transition metal catalyzed cross-coupling reaction](#). The reaction couples [organic halides](#) or [triflates](#) with [organozinc compounds](#), forming [carbon-carbon bonds \(c-c\)](#) in the process. A [palladium \(0\)](#) species is generally utilized as the metal catalyst, though [nickel](#) is sometimes used.^{[1][2]}

Negishi coupling	
Named after	Ei-ichi Negishi
Reaction type	Coupling reaction
Identifiers	
Organic Chemistry Portal	negishi-coupling
RSC ontology ID	RXNO.0000088

CONCEPTS AND RXNO

1 Heteroatom alkylation and arylation

.7 O-substitution

- .1 Chan-Lam ether coupling
- .2 Diazomethane esterification
- .3 Ethyl esterification
- .4 Hydroxy to methoxy
- .5 Hydroxy to triflyloxy
- .6 Methyl esterification

.n

2 Acylation and related processes

.6 O-acylation to ester

- .1 Ester Schotten-Baumann
- .2 Esterification (generic)
- .3 Fischer-Speier esterification
- .4 Baeyer-Villiger oxidation
- .5 Yamaguchi esterification
- .6 Hydroxy to imidazolecarbonyloxy
- .7 Imidazolecarbonyl to ester
- .8 Hydroxy to acetoxy
- .9 Steglich esterification

.n



CONCEPTS AND RXNO

1 Heteroatom alkylation and arylation

.7 O-substitution

.1 Chan-Lam ether coupling

.2 Diazomethane esterification

.3 Ethyl esterification

.4 Hydroxy to methoxy

.5 Hydroxy to triflyloxy

.6 Methyl esterification

.n

2 Acylation and related processes

.6 O-acylation to ester

.1 Ester Schotten-Baumann

.2 Esterification (generic)

.3 Fischer-Speier esterification

.4 Baeyer-Villiger oxidation

.5 Yamaguchi esterification

.6 Hydroxy to imidazolecarbonyloxy

.7 Imidazolecarbonyl to ester

.8 Hydroxy to acetoxy

.9 Steglich esterification

.n

Esterification (7)

Chan-Lam coupling (3)

Schotten-Baumann Reaction (9)

RXNO: <http://github.com/rsc-ontologies/rxno>




NAMERXN

Assigns reactions to **1150+** reaction categories using transformations

Can guarantee **perfect** Atom-Atom Mapping

- Atom-Atom Mapping is an output **not** an input
- MCS mappers struggle with rearrangements:



EXAMPLE SMARTS/SMIRKS

```
# NOZAKI_HIYAMA_KISHI_REACTION
```

```
[#6v4+0;X4,X3:1][BrD1h0+0:2].[Ni].[Cr].[OD1h0+0:3]=[CD2h1v4+0:4]>>[#6:1][C:4]-[Oh1:3]
```


```
# PAAL_KNORR_THIOPHENE_SYNTHESIS
```

```
[OD1h0+0:1]=[CX3v4+0:2][CX4v4+0:3]([H])[CX4v4+0:4]([H])[CX3v4+0:5]=[OD1h0+0:6]>>[S:1]1[C:2]=[C:3][C:4]=[C:5]1
```

- Writing SMIRKS is both an art and a science.



ATOM MAPPING + CLASSIFICATION



10 MOST POPULAR REACTIONS

ID	Name	Count
2.1.2	Carboxylic acid + amine	26,040
1.3.1	Buchwald-Hartwig amination	22,048
3.1	Suzuki coupling	16,508
1.7.6	Williamson ether synthesis	15,665
2.1.1	Amide Schotten-Baumann	11,016
7.1	Nitro to amino	10,234
6.1.1	N-Boc deprotection	9,821
6.2.2	CO ₂ H-Me deprotection	9,487
6.2.1	CO ₂ H-Et deprotection	6,749
2.2.3	Sulfonamide Schotten-Baumann	6,223




MOST/LEAST SUCCESSFUL REACTIONS

ID	Name	Mean Yield	Count
1.7.2	Diazomethane esterification	91%	41
9.3.1	Carboxylic acid to acid chloride	88%	704
9.7.14	Bromo to azido	85%	235
1.7.5	Methyl esterification	84%	2918
9.7.19	Bromo to iodo Finkelstein reaction	82%	116
6.1.3	N-Cbz deprotection	81%	1359
	...		
4.1.11	Larock indole synthesis	47%	55
3.11.3	Ullmann-type biaryl coupling	44%	407
1.7.1	Chan-Lam ether coupling	44%	154
4.1.4	Pinner pyrimidine synthesis	39%	47



TRENDS IN REACTION TYPES




SUZUKI COUPLING LEAVING GROUPS

Leaving Group	Mean Yield	N Observations
Bromo	58.80%	10817
Chloro	57.96%	2752
Iodo	57.21%	2049
Triflyloxy	65.48%	717



TRENDS IN SOLVENT USE



ARE SOLVENTS GETTING GREENER?

1976	2013
Water (21%)	Tetrahydrofuran (15%)
Ethanol (11%)	Dichloromethane (14%)
Benzene (8%)	Water (13%)
Methanol (7%)	Dimethylformamide (10%)
Tetrahydrofuran (5%)	Methanol (8%)
Dichloromethane (4%)	Ethyl acetate (7%)
Dimethylformamide (4%)	Ethanol (5%)
Acetic acid (4%)	1,4-Dioxane (4%)
Chloroform (3%)	Toluene (3%)
Acetone (3%)	Acetonitrile (3%)
Total for top 10: 71%	82%



RARE NAMED REACTIONS

- Adams decarboxylation
- Angeli-Rimini reaction
- Aza-Baylis-Hillman reaction
- Boyer reaction
- Buchwald-Fischer indole synthesis
- Castro-Stephens coupling
- **Chapman rearrangement**
- Chugaev elimination
- Cook-Heilbron thiazole synthesis
- Fischer-Hepp rearrangement
- Gasman indole synthesis
- Fukuyama indole synthesis
- Imine Hosomi-Sakurai reaction
- Koch reaction
- Leuckart reaction
- Liebeskind-Srogl coupling
- Lossen rearrangement
- Ponzio reaction
- Prins reaction
- Reimer-Tiemann carboxylation




ANALYSIS VS. PREDICTION




MAJOR HURRICANE IRMA (AL11)

EPS track guidance initialized at 1200 UTC, 06 September 2017



THE CHALLENGE OF REGIOSELECTIVITY

- A tricky benchmark is reactions of 2,4,5-trichloropyrimidine




- The nature of pyrimidine makes the chloro at the 4-position more reactive than the 2 position which is more reactive than the 5 position.
- Simple quantum mechanical have difficulty discerning this order.



APPLICATION TO PLANNING 1


- Cinnamic Acid (PhCHCHCO_2)

1. Bromo Heck reaction (272)
2. Horner-Wadsworth-Emmons reaction (268)
3. Wittig olefination (129)
4. Bromo Heck-type reaction (62)
5. Iodo Heck reaction (49)
6. Triflyloxy Heck[-type] reaction (43)
7. Ester Schotten-Baumann (10)
8. Bromo Suzuki coupling (5)
9. Stille reaction (2)
10. Olefin metathesis (1)




APPLICATION TO PLANNING 2

- p-Nitrotoluene



1. Nitration (96)
2. Bromo Suzuki-type (1)
3. Chloro Suzuki (1)

- p-Nitrobenzoic acid




1. Nitrile to carboxy (12)
2. CO₂H-Me deprot (8)
3. CO₂H-Et deprot (5)
4. Ester hydrolysis (1)
5. Nitration (1)



EXPERIMENTAL VALIDATION



- Synthesis of a novel aromatic heterocycle previously unreported in the scientific literature.
- William Pitt et al., “Heteroaromatic Rings of the Future”, *Journal of Medicinal Chemistry*, 52(9):2952-2963, 2009.



ACKNOWLEDGEMENTS

- NextMove Software
- NextMove Alumni
 - Daniel Lowe
 - Noel O'Boyle
- Thank you for you time.
- Questions?
- Thoughts?

- AbbVie
- AstraZeneca
- Bristol-Myers Squibb
- **Eli Lilly**
- GlaxoSmithKline
- Hoffmann-La Roche
- **IBM Research Zurich**
- IKTOS
- Merck
- **MIT**
- **Novartis**
- PendingAI
- Relay Therapeutics
- Royal Society of Chemistry
- Syngenta
- Vernalis
- Vertex Pharmaceuticals
- WuXi



NAMERXN NAMING RESOURCES

- L. Kurti and B. Czako, “Strategic Applications of Named Reactions in Organic Synthesis”, Elsevier, 2005.
- A. Hassner and I. Namboothiri, “Organic Synthesis based on Name Reactions”, Elsevier, 3rd Edition 2011.
- The Merck Index, 15th Edition 2003. (13th Edition 2001).
- J.J. Li, “Name Reactions”, Springer, 5th Edition, 2019.
- github.com/rsc-ontologies/rxno
- Wikipedia

